These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19047284)

  • 41. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amyloidosis and Waldenström's macroglobulinemia.
    Gertz MA; Merlini G; Treon SP
    Hematology Am Soc Hematol Educ Program; 2004; ():257-82. PubMed ID: 15561687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
    Castillo JJ; Ghobrial IM; Treon SP
    Cancer Treat Res; 2015; 165():177-95. PubMed ID: 25655610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Waldenstrom macroglobulinemia.
    Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
    Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
    Thomas SK
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.
    Berentsen S
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):110-2. PubMed ID: 19362990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
    Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
    Ise M; Sakai C; Kumagai K
    Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
    Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
    Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Report of consensus panel 1 from the 11
    Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
    Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Waldenström's macroglobulinemia: prognostic factors and recent therapeutic advances.
    Leblond V; Tournilhac O; Morel P
    Clin Exp Med; 2004 Apr; 3(4):187-98. PubMed ID: 15103509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Waldenström macroglobulinemia].
    Telek B; Batár P; Váróczy L; Gergely L; Rejtő L; Szász R; Miltényi Z; Simon Z; Udvardy M; Illés A
    Orv Hetil; 2013 Dec; 154(50):1970-4. PubMed ID: 24317355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Waldenström's macroglobulinaemia: laboratory diagnosis and treatment.
    Owen RG; Johnson SA; Morgan GJ
    Hematol Oncol; 2000 Jun; 18(2):41-9. PubMed ID: 10960874
    [No Abstract]   [Full Text] [Related]  

  • 60. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
    Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
    J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.